← Leaderboards
David H. Gutmann
Washington University
$29,869,613
Attributed
$33,156,178
Total exposure
19
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.3M · FY2006–25$10M$7.5M$5M$2.5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$33,156,178 · 19
By mechanism
R01$17,328,105 · 11
R35$6,568,742 · 2
U01$4,779,666 · 1
RC4$3,300,000 · 1
R21$703,539 · 2
UE5$406,126 · 1
Top collaborators
- Joshua B Rubin5 shared
- Michelle Monje-Deisseroth4 shared
- David R Piwnica-Worms4 shared
- Jason Weber4 shared
- Gregory J Zipfel1 shared
Most similar at Washington University
Same institution · by research overlap
- Joshua L Morgan$2,161,240
- Jason Weber$7,135,661
- Joshua B Rubin$9,646,572
- David R Piwnica-Worms$22,122,563
- Vaishali Kapoor$459,633
Others in their field
Top investigators on “Glioma”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$158,144,386
- Todd A Alonzo · University Of Colorado Denver/Hsc Denver$72,436,447
- David Heimbrook · Leidos Biomedical Research, Inc.$56,561,099
- Gregory H Reaman · National Childhood Cancer Foundation$49,046,612
- Melissa L Bondy · Stanford University$36,047,564
- Brad H. Pollock · University Of Florida$28,646,726
Research focus
GliomaChildBrain NeoplasmsGrowthNeurofibromatosis 1MolecularTumorGenetically Engineered MouseBasePathway InteractionsLaboratoriesAffectMouse StrainsAstrocytomaCellsBrainNf1 GeneIn VivoOpticsGene MutationMouse ModelResearch PersonnelAstrocytesOptic Nerve Glioma
Grant awards (73)
T Cell Regulation of Low-Grade Glioma$950,428
R01 · FY2025 · CA · contact PI
Modeling neurofibromatosis-1 disease heterogeneity to optimize risk assessment and treatment$877,001
R35 · FY2025 · NS · contact PI
Neuronal Regulation of Low-Grade Gliomagenesis$632,250
R01 · FY2025 · CA
Washington University Physician Neuroscientist Training Pipeline (PNTP) Pathway$406,126
UE5 · FY2025 · NS
Defining the Mechanistic Basis for Neurofibromatosis-1 Nervous System Disease Heterogeneity$739,624
R35 · FY2024 · NS · contact PI
Neuronal Regulation of Low-Grade Gliomagenesis$603,598
R01 · FY2024 · CA
T Cell Regulation of Low-Grade Glioma$440,179
R01 · FY2024 · CA · contact PI
Defining the Mechanistic Basis for Neurofibromatosis-1 Nervous System Disease Heterogeneity$762,500
R35 · FY2023 · NS · contact PI
Neuronal Regulation of Low-Grade Gliomagenesis$625,706
R01 · FY2023 · CA
T Cell Regulation of Low-Grade Glioma$483,265
R01 · FY2023 · CA · contact PI
Defining the Mechanistic Basis for Neurofibromatosis-1 Nervous System Disease Heterogeneity$686,252
R35 · FY2022 · NS · contact PI
Neuronal Regulation of Low-Grade Gliomagenesis$657,214
R01 · FY2022 · CA
T Cell Regulation of Low-Grade Glioma$479,365
R01 · FY2022 · CA · contact PI
Defining the Mechanistic Basis for Neurofibromatosis-1 Nervous System Disease Heterogeneity$76,250
R35 · FY2022 · NS · contact PI
Defining the Mechanistic Basis for Neurofibromatosis-1 Nervous System Disease Heterogeneity$686,252
R35 · FY2021 · NS · contact PI
Defining the Mechanistic Basis for Neurofibromatosis-1 Nervous System Disease Heterogeneity$686,250
R35 · FY2020 · NS · contact PI
DEFINING RISK FACTORS FOR NF1-OPTIC GLIOMA$348,844
R01 · FY2020 · CA · contact PI
Defining the Mechanistic Basis for Neurofibromatosis-1 Nervous System Disease Heterogeneity$686,250
R35 · FY2019 · NS · contact PI
DEFINING RISK FACTORS FOR NF1-OPTIC GLIOMA$338,378
R01 · FY2019 · CA · contact PI
Defining the Mechanistic Basis for Neurofibromatosis-1 Nervous System Disease Heterogeneity$684,641
R35 · FY2018 · NS · contact PI
DEFINING RISK FACTORS FOR NF1-OPTIC GLIOMA$348,844
R01 · FY2018 · CA · contact PI
Defining the Mechanistic Basis for Neurofibromatosis-1 Nervous System Disease Heterogeneity$683,722
R35 · FY2017 · NS · contact PI
Leveraging Genetically-Engineered Mice to Optimize Pediatric Glioma Management$551,530
R01 · FY2017 · CA · contact PI
DEFINING RISK FACTORS FOR NF1-OPTIC GLIOMA$348,844
R01 · FY2017 · CA · contact PI
Leveraging Genetically-Engineered Mice to Optimize Pediatric Glioma Management$564,104
R01 · FY2016 · CA · contact PI
DEFINING RISK FACTORS FOR NF1-OPTIC GLIOMA$348,844
R01 · FY2016 · CA · contact PI
Leveraging Genetically-Engineered Mice to Optimize Pediatric Glioma Management$584,882
R01 · FY2015 · CA · contact PI
NEUROFIBROMIN REGULATION OF NEURAL STEM CELL FUNCTION IN VITRO AND IN VIVO$322,591
R01 · FY2014 · NS · contact PI
Targeting Stoma-Tumor Co-Dependency for Glioma Therapy$709,767
U01 · FY2013 · CA · contact PI
NEUROFIBROMIN REGULATION OF NEURAL STEM CELL FUNCTION IN VITRO AND IN VIVO$314,445
R01 · FY2013 · NS · contact PI
STROMAL CONTRIBUTIONS TO NF1 GLIOMA FORMATION AND GROWTH$287,582
R01 · FY2013 · CA
Targeting Stoma-Tumor Co-Dependency for Glioma Therapy$77,646
U01 · FY2013 · CA · contact PI
Targeting Stoma-Tumor Co-Dependency for Glioma Therapy$754,845
U01 · FY2012 · CA · contact PI
NEUROFIBROMIN REGULATION OF NEURAL STEM CELL FUNCTION IN VITRO AND IN VIVO$325,850
R01 · FY2012 · NS · contact PI
STROMAL CONTRIBUTIONS TO NF1 GLIOMA FORMATION AND GROWTH$305,938
R01 · FY2012 · CA
Targeting Stoma-Tumor Co-Dependency for Glioma Therapy$82,601
U01 · FY2012 · CA · contact PI
Targeting Stoma-Tumor Co-Dependency for Glioma Therapy$1,332,595
U01 · FY2011 · CA · contact PI
REGULATION AND ROLE OF MTOR IN NEUROFIBROMIN GROWTH CONTROL$404,112
R01 · FY2011 · CA
NEUROFIBROMIN REGULATION OF NEURAL STEM CELL FUNCTION IN VITRO AND IN VIVO$325,850
R01 · FY2011 · NS · contact PI
STROMAL CONTRIBUTIONS TO NF1 GLIOMA FORMATION AND GROWTH$305,938
R01 · FY2011 · CA
Targeting Stoma-Tumor Co-Dependency for Glioma Therapy$82,601
U01 · FY2011 · CA · contact PI
Integrative Approaches to Stroma-Directed Glioma Therapy$3,300,000
RC4 · FY2010 · NS · contact PI
Targeting Stoma-Tumor Co-Dependency for Glioma Therapy$832,584
U01 · FY2010 · CA · contact PI
REGULATION AND ROLE OF MTOR IN NEUROFIBROMIN GROWTH CONTROL$469,859
R01 · FY2010 · CA
NEUROFIBROMIN REGULATION OF NEURAL STEM CELL FUNCTION IN VITRO AND IN VIVO$323,400
R01 · FY2010 · NS · contact PI
STROMAL CONTRIBUTIONS TO NF1 GLIOMA FORMATION AND GROWTH$315,400
R01 · FY2010 · CA
Targeting Stoma-Tumor Co-Dependency for Glioma Therapy$85,120
U01 · FY2010 · CA · contact PI
Targeting Stoma-Tumor Co-Dependency for Glioma Therapy$821,907
U01 · FY2009 · CA · contact PI
REGULATION AND ROLE OF MTOR IN NEUROFIBROMIN GROWTH CONTROL$372,952
R01 · FY2009 · CA
STROMAL CONTRIBUTIONS TO NF1 GLIOMA FORMATION AND GROWTH$315,400
R01 · FY2009 · CA
REGULATION AND ROLE OF MTOR IN NEUROFIBROMIN GROWTH CONTROL$341,561
R01 · FY2008 · CA
Molecular Determinants of Neural Stem Cell Function$166,250
R21 · FY2008 · NS · contact PI
Molecular Determinants of Neural Stem Cell Function$199,500
R21 · FY2007 · NS · contact PI
Identification and Preclinical Evaluation of New Brain Tumor Therapies$166,132
R21 · FY2007 · NS · contact PI
Identification and Preclinical Evaluation of New Brain Tumor Therapies$171,657
R21 · FY2006 · NS · contact PI
PRECLINICAL MODELS FOR HUMAN ASTROCYTOMAS$297,900
R01 · FY2004 · NS
FUNCTIONAL ANALYSIS OF NF2 GENE MUTATIONS$308,000
R01 · FY2003 · NS
PRECLINICAL MODELS FOR HUMAN ASTROCYTOMAS$297,900
R01 · FY2003 · NS
PROTEIN 4.1 TUMOR SUPPRESSORS IN MENINGIOMA PATHOGENESIS$256,160
R01 · FY2003 · NS
Neurofibromatosis Foundation International Consortium$70,000
R13 · FY2003 · NS
NEUROFIBROMIN AS A NEGATIVE REGULATOR FOR ASTROCYTES$313,970
R01 · FY2002 · NS
FUNCTIONAL ANALYSIS OF NF2 GENE MUTATIONS$308,000
R01 · FY2002 · NS
PRECLINICAL MODELS FOR HUMAN ASTROCYTOMAS$297,900
R01 · FY2002 · NS
PROTEIN 4.1 TUMOR SUPPRESSORS IN MENINGIOMA PATHOGENESIS$256,160
R01 · FY2002 · NS
PRECLINICAL MODELS FOR HUMAN ASTROCYTOMAS$30,000
R01 · FY2002 · NS
NEUROFIBROMIN AS A NEGATIVE REGULATOR FOR ASTROCYTES$318,028
R01 · FY2001 · NS
PRECLINICAL MODELS FOR HUMAN ASTROCYTOMAS$311,400
R01 · FY2001 · NS
FUNCTIONAL ANALYSIS OF NF2 GENE MUTATIONS$308,000
R01 · FY2001 · NS
PROTEIN 4.1 TUMOR SUPPRESSORS IN MENINGIOMA PATHOGENESIS$294,768
R01 · FY2001 · NS
FUNCTIONAL ANALYSIS OF NF2 GENE MUTATIONS$334,000
R01 · FY2000 · NS
NEUROFIBROMIN AS A NEGATIVE REGULATOR FOR ASTROCYTES$308,766
R01 · FY2000 · NS
NEUROFIBROMIN AS A NEGATIVE REGULATOR FOR ASTROCYTES$25,000
R01 · FY2000 · NS
FUNCTIONAL ANALYSIS OF NF2 GENE MUTATIONS$25,000
R01 · FY2000 · NS